Sun Pharma faces profit dip amid cost pressures in US

Pharmaceutical giant Sun Pharmaceutical Industries is anticipated to report consistent revenue growth, albeit with subdued profitability in its results for the September 2025 quarter (Q2FY26), impacted by increased costs associated with its US specialty portfolio.

Estimates from various brokerages suggest that the company’s revenue is expected to increase by approximately 7 percent year-on-year, fueled by robust performance in both domestic and specialty sectors, while net profit may experience a slight decline due to heightened promotional and R&D expenditures.

The Mumbai-based company is set to release its results for the July–September quarter (Q2FY26) on Wednesday, November 5, 2025.

Also Read: AstraZeneca Gets Nod to Update Lokelma for Hyperkalemia

 Sun Pharma's net profit is projected to be ?2,843.4 crore, reflecting an average year-on-year decline of 3 percent, compared to ?2,932.3 crore in the same quarter last year (Q2FY25). On a quarterly (Q-o-Q) basis, the company’s net income is expected to decrease by an average of 5 percent. Sun Pharmaceutical Industries Limited (doing business as Sun Pharma) is an Indian multinational pharmaceutical corporation headquartered in Mumbai.

It produces and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in over 100 countries. It stands as the largest pharmaceutical company in India and ranks as the fourth largest specialty generic pharmaceutical firm globally.

Approximately 70% of Sun Pharma’s revenue is derived from international markets, with the US and India being the primary markets, contributing to over 60% of the company’s total revenue.

Manufacturing operations are conducted across 43 locations in India, the US, Asia, Africa, Australia, and Europe. The product range addresses therapeutic areas including psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental, and nutritionals. Its active pharmaceutical products feature baricitinib, brivaracetam, and dapagliflozin.